This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biogen's Alzheimer Disease Candidate Succeeds in Phase II
by Zacks Equity Research
Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.
Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
by Zacks Equity Research
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.
3 Buy-Rated Large Cap Pharma Stocks to Boost Health in July
by Madhu Goel
We take a look at the three large cap pharma stocks that might be best bargains for the month of July.
Here's Why AbbVie Stock is Good for Your Portfolio's Health
by Zacks Equity Research
Here are six reasons why investing in AbbVie (ABBV) stock is a good decision now.
Is Pfizer's Price Hike an Effect of Drug Policy on Sector?
by Zacks Equity Research
Pfizer (PFE) reportedly raises prices of almost 100 drugs. The new drug policy has a soft stance with no provisions for direct negotiation by Medicare and resorts to competition for restricting price.
Fortive Set to Buy Gordian, Expands Field Solutions Portfolio
by Zacks Equity Research
Fortive's (FTV) plans to acquire Gordian. The buyout is likely to add strength to Professional Instrumentation and Industrial Technologies segments.
4 Drug and Biotech Stocks Awaiting FDA Decisions in July
by Kinjel Shah
In the first six months of the year, the FDA grants approval to 17 new treatments.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, General Motors, Valero and Ameriprise
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, General Motors, Valero and Ameriprise
Amgen Announces Top-Line Data From Remicade Biosimilar Study
by Zacks Equity Research
Amgen (AMGN) presents top-line results from a late-stage study evaluating its biosimilar version of Remicade. Data shows that there was no clinically meaningful difference between the two products.
Top Analyst Reports for Johnson & Johnson, Biogen & General Motors
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Biogen (BIIB) and General Motors (GM).
AbbVie (ABBV), Calico Extend R&D Deal, to Invest $500M Each
by Zacks Equity Research
AbbVie (ABBV) and Alphabet backed biotech Calico Life Sciences extend their 2014 R&D collaboration by investing another $500 million each to develop candidates to treat age-related diseases.
AbbVie's (ABBV) Imbruvica sNDA Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants a priority review to AbbVie's (ABBV) lymphoma drug Imbruvica sNDA, for the treatment of Waldenstr??m's macroglobulinemia (WM).
Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III
by Zacks Equity Research
Glaxo's (GSK) two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine showed non-inferiority to a standard three-drug regimen
Dow 30 Stock Roundup: Caterpillar Raises Dividend, Merck's Keytruda Gets FDA Nod
by Swarup Gupta
The Dow traversed a tough week, suffering losses for three consecutive sessions.
Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health
by Zacks Equity Research
Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health
Growth & Income Buys | Johnson & Johnson and International Paper
by Brian Hamilton
This week's video covers two companies where management has made key decisions for the future of their respective companies; Johnson & Johnson (JNJ), and International Paper (IP).
J&J (JNJ) Accepts Platinum Equity's Offer for LifeScan Unit
by Zacks Equity Research
Johnson & Johnson (JNJ) to sell its LifeScan diabetes device unit to Platinum Equity.
Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate
by Zacks Equity Research
Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.
Amgen Gets FDA Nod to Add ASPIRE Data on Kyprolis Label
by Zacks Equity Research
Amgen (AMGN) gets FDA approval to add overall survival data from the phase III ASPIRE study on the label of its multiple myeloma drug, Kyprolis.
Stryker Likely to Acquire Boston Scientific, Shares Down
by Zacks Equity Research
Per Reuters and The Wall Street Journal, Stryker (SYK) is likely to acquire Boston Scientific. However, there are no confirmatory statements from the company representatives.
Dow 30 Stock Roundup: UnitedHealth Hikes Quarterly Dividend by 20%, Microsoft Confirms GitHub Buyout
by Swarup Gupta
The Dow enjoyed a week of steady gains with trade concerns largely taking a backseat.
Fortive Plans to Buy Johnson & Johnson's Sterilization Unit
by Zacks Equity Research
Fortive (FTV) is likely to enter the medical sterilization and disinfection market with its intended purchase of Johnson & Johnson's Sterilization business.
J&J Receives Buyout Offer for Sterilization Products Unit
by Zacks Equity Research
Johnson & Johnson (JNJ) receives a binding offer worth $2.8 billion from Fortive Corporation for its sterilization products business.
3 Biotech Stocks Up in the Past Month on Industry Turnaround
by Zacks Equity Research
We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.
Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
The FDA approves Pfizer's (PFE) sNDA seeking label expansion in third indication for Xeljanz to include moderately to severely active ulcerative colitis.